In a woman with obesity and newly diagnosed type 2 diabetes, subcutaneous semaglutide was followed by a marked and rapid normalisation of persistently elevated alanine aminotransferase.
In plain wordsIn one woman with obesity and type 2 diabetes, raised liver enzyme levels returned to normal after she started semaglutide injections.
- Peptide
- Semaglutide
- Outcome
- DecreaseAlanine aminotransferase normalisation
- Study
n = 1
- Outcome group
- Liver fat and liver function · Liver
- Studied dose
- Dose not stated · subcutaneousAs given in this study (human).
Source sentences
In this case report, we presented a 28-year-old White Hispanic female with Class I obesity and newly diagnosed type 2 diabetes who demonstrated a marked and rapid normalization of persistently elevated alanine aminotransferase levels following the initiation of subcutaneous semaglutide therapy.